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Abstract 
Introduction: The relationship between iron deficiency and vitamin B12 and 
folate was recognized several decades ago. Combined deficiency is important in 
clinical practice owing to its relationship with malabsorption syndromes. By 
contrast, iron deficiency and low levels of serum vitamin B12 with normal 
metabolic markers were often found mostly in young adults. In this work vitamin 
B12/folate changes were investigated during treatment of iron deficiency anemia 
(IDA) with pharmacological iron in young adult women.  
Methods: A cohort of 35 young adult women with IDA were treated with oral iron 
An haematological response was obtained in 97.2 % at 4-month follow-up. 
Changes in serum vitamin B12, serum folate, and other biochemical parameters 
were monitored. 
Results: Treatment with iron increased significantly serum folate and vitamin B12 
from baseline. This increase was also observed in vitamin B12 levels ≤200 pmol/l 
(6 patients, 17.1%), in whom serum vitamin B12 was above 200 pmol/l at the end 
of the study in all cases. Other biochemical parameters also changed. Significant 
increases were seen for glucose (p=0.012), uric acid (p<0.001), total cholesterol 
(p=0.023), HDL-cholesterol (p=0.026), and bilirubin (p<0.001). Urea decreased 
significantly (p=0.036). 
Conclusions: Data from our work suggest that iron deficiency could affect many 
metabolic pathways, including vitamin B12, folate, and lipids. These changes 
normalise after iron therapy, even in women with baseline low levels of serum 
vitamin B12. Healthcare practitioners should be aware of these changes in IDA 
management. The mechanisms controlling these changes remain to be explained, 
but they are probably related to the control of iron homeostasis (iron deficiency 
mediated stimuli).   
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Introduction 
The relationship between iron deficiency and vitamin B12 deficiency was 
recognized several decades ago [1–4]. Vitamin B12 deficiency is relatively 
common, but the majority of subjects in epidemiological studies have subclinical 
vitamin B12 deficiency, and do not present the classic signs of clinical deficiency [1, 
5]. However, patients with subnormal vitamin B12 levels and normal vitamin B12 
related metabolites (homocysteine and methylmalonic acid) are not uncommon 
and are often found in pregnancy, iron deficiency, HIV infection, etc. [1, 2, 6, 7]. 
Such patients must be differentiated from subjects with iron deficiency and low 
serum cobalamin levels, but a real cobalamin deficiency [3, 7–9]. Moreover, low-
normal or borderline values of cobalamin (150-200 pmol/l or 250 pmol/l) are far 
more common (for instance, 15-20% of western population), especially in the 
elderly [1, 2, 5, 7, 10, 11]. 
Among the elderly, combined iron deficiency and vitamin B12 deficiency have been 
found in some of these subjects using vitamin metabolic markers [7, 12]. By 
contrast, iron deficiency and low levels of serum vitamin B12 with normal 
metabolic markers were often found mostly in young adults [1, 7, 13].  
Combined deficiency is important in clinical practice owing to its relationship with 
malabsorption related syndromes, such as pernicious anemia, Helicobacter pylori 
infection, celiac disease, and gastrectomy/gastroplasty [14]. These disorders 
induce refractory or unexplained iron deficiency, a frequent cause for consultation 
in Hematology.  The etiologic approach to these patients with combined deficiency 
is different, and the aforementioned causes should be rapidly confirmed or 
discarded [15]. 
Since iron deficiency anaemia is the most frequent cause of anaemia [16], and since 
clinical and diagnostic outcomes are conditioned by coexisting vitamin B12 
deficiency, a flowchart to decide whether to perform vitamin assay for normocytic 
or microcytic anaemic patients was necessary. Using age over 60 years as a cut-off, 
most patients with combined deficiency could be identified [7] . But, as stated 
above, low vitamin B12 with normal vitamin related metabolites was often found 
in iron deficiency anaemia below this age[1, 7, 13].   
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The aim of this work was to investigate vitamin B12/folate changes in young 
adults and during treatment of iron deficiency anemia (IDA) with pharmacological 
iron. In addition, changes in other biochemical variables were also evaluated. 
 
Materials and methods 
Subjects 
Patients were recruited at Complejo Hospitalario de Toledo, Spain. Inclusion 
criteria were: Caucasian women aged 18-40 years, haemoglobin ≤ 110 g/L, mean 
corpuscular volume (MCV) < 98 fL, erythrocyte sedimentation rate (ESR)< 40 mm 
Hg, transferrin saturation <15% and ferritin < 20 µg/l, or if ferritin was 20-50 µg/l, 
also soluble transferrin receptor (sTfR) > 5 mg/l. Exclusion criteria were: 
amenorrhoea, menopause, smoker, pregnancy, breast-feeding, non-Caucasian, 
thalassemia, iron-metabolism related diseases such as haemochromatosis, 
autoimmune diseases, chronic gastrointestinal diseases (inflammatory bowel 
disease, gastric ulcers, coeliac disease, Crohn’s disease), neoplastic diseases, renal 
disease or hormone related diseases independent of iron-deficiency anaemia, C-
reactive protein > 5 mg/L, creatinine levels > 1,0 mg/L (120 µmol/L), abnormal 
liver tests (> 2 times normal), blood donation in the past 3 months or currently 
taking pharmacological iron supplements.  
Over 18 months, 84 women who met the inclusion criteria were interviewed by 
telephone to assess all exclusion criteria. After the exclusion criteria were applied, 
36 women agreed to participate; one subject abandoned the study due to a change 
of residence.  
The Complejo Hospitalario de Toledo Clinical Research Ethics Committee, Spain 
and the Spanish National Research Council Ethics Committee (Bioethics 
subcommittee) approved the present study. The study was conducted according to 
guidelines laid down in the Declaration of Helsinki, and participants gave signed 
written consent. 
 
Study Protocol 
On their first visit, patients were prescribed an eight-week supply of 
pharmacological iron in the form of ferrous sulphate tablets: 1 tablet (80 mg Fe) 
daily if haemoglobin > 100 g/L or 2 tablets a day (160 mg Fe) if haemoglobin <100 
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g/L. Patients were instructed to take the tablets in fasting conditions with water or 
orange juice.  
A follow-up visit was scheduled 9 weeks after the baseline visit, one week after 
completing the prescribed pharmacological treatment to allow iron levels to 
stabilise.  
If patients had not recovered from anaemia and / or iron deficiency after the first 
8-week cycle of treatment (haemoglobin> 120 g/L and ferritin ≥ 15 µg/L), a 
further 8 weeks of treatment was prescribed, with a second follow-up visit 
scheduled one week after finishing the second cycle of treatment. 
The compliance of the study was assessed by questionnaires and a personal 
interview in each visit. Patients were asked about the number of tablets that were 
taken throughout treatment. 
Complete response was defined by normalisation of Hb (Hb > 120 g/l) and serum 
ferritin ≥ 15 µg/l.  Incomplete response was defined by normalization of Hb (Hb > 
120 g/l) but serum ferrritin < 15 µg/l, or an increase of Hb ≥ 20 g/l.  
Blood samples and anthropometric measurements were taken and clinical, 
gynaecological, and dietary questionnaires were completed at every visit. Body 
weight was measured at baseline using a Seca scale (to a precision of 100 g) and 
height was measured (at baseline only) with a stadiometer incorporated into the 
scale. Body mass index (BMI) was calculated as weight/height squared (kg/m2). 
Blood samples were collected between 8:00 and 10:00 by venepuncture after a 12-
hour fasting period. Serum was obtained after centrifugation (for 5 minutes at 
1000g).  
 
Dietary assessment 
Baseline food, energy and nutrient intakes were assessed with a 72-hour detailed 
dietary report previously validated in iron deficient women (17,18). The possible 
food intake changes throughout the study were monitored using a food frequency 
questionnaire. 
 
Haematological and Biochemical assays 
Total blood cell counts and ESR were determined in whole blood following 
standard laboratory techniques using the Beckman Coulter LH780 
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Analyzer (Beckman Coulter, Brea, California). Serum iron, serum ferritin, total iron 
binding capacity, serum vitamin B12, serum folate, sTfR, and other biochemical 
variables were determined by modular analysers (Elecsys and Modular DP, Roche 
Diagnostics, Mannheim, Germany).  
 
Statistical Analysis 
Data analysis was carried out using R software (version 3.0.1). Non-normally 
distributed continuous variables were log-transformed and results are presented 
as means with their standard deviations. Differences between baseline and end of 
treatment for iron biomarkers and biochemical parameters were compared using 
paired t-tests. Differences between groups for hematological parameters according 
to folate and vitamin B12 levels were performed by analysis of variance (ANOVA). 
Pearson correlation test was performed to study the correlation between the 
changes in Hb and biochemical parameters. Values of p < 0.05 were considered 
significant. Ordinal variables were compared using Wilcoxon Signed Rank Test.  
 
Results 
 
Thirty-five women were included and completed the study. The subjects were aged 
35.3 5.3 years. BMI was 26.1  4.6 kg/m2 at baseline and did not significantly vary 
throughout treatment (26.0  4.5 kg/m2 at end of treatment).  No significant 
changes were seen in food intake between baseline and end of treatment, 
measured by the food frequency questionnaire, except for “Fruit juices at 
breakfast” which showed an increased consumption (median increased from 0 to 
1) (p=0.015) and “Other dairy products at breakfast” which decreased (although 
median is 0 at both timepoints) (p=0.022) (table1).  
Table 2 shows the changes in blood cell counts and iron biomarkers from baseline 
to the end of treatment. Incomplete or complete response was observed in 97.2 % 
(at 4-month follow-up, 77% complete responses and 20% incomplete responses).  
Treatment with iron increased significantly serum folate and vitamin B12 from 
baseline (table 2). In vitamin B12 this increase was observed in patients with 
vitamin B12 levels ≤200 pmol/l (6 cases, 17.1%, including 5 with serum folate ≤13 
7 
nmol/l). At the end of the study serum vitamin B12 was higher than 200 pmol/l in 
all patients (table 3).   
Table 4 shows changes from baseline to the end of treatment for other biochemical 
parameters. Significant increases were seen for glucose (p=0.012), uric acid 
(p<0.001), total cholesterol (p=0.023), HDL-cholesterol (p=0.026), and bilirubin 
(p<0.001). Urea decreased significantly (p=0.036), and creatinine, proteins, 
albumin, triglycerides and LDL-cholesterol had no significant changes. 
Patients with B12 <200 pmol/L (n=6) did not show significant differences in 
hematologic parameters compared to those patients with only iron deficiency. 
However, patients with folate <13 nmol/L (n=8) presented lower hemoglobin, 
MCV, MCHC, serum iron and transferrin saturation, and higher sTrR levels 
compared to the other patients (table 5). No correlation between the Hb increase 
and the increases in the biochemical parameters were observed. However, serum 
vitamin B12 and serum folate changes were correlated (r =0. 406; p= 0.017). 
 
Discussion 
 
The purpose of this study was to investigate serum vitamin B12 and folate changes 
during treatment of IDA with ferrous sulphate. It was found that the recovery from 
IDA was accompanied by an increase in levels of vitamin B12, especially in cases 
with the lowest levels of serum vitamin B12, and folic acid. Moreover other 
biochemical significant variations were observed. For instance, glucose, total 
cholesterol and HDL cholesterol increased. These findings should be taken into 
account by healthcare practitioners dealing with IDA management. 
In this group, energy intake was adequate for women of their age and activity 
levels. Protein intake was marginally higher than recommended, whilst 
carbohydrate intake was lower and lipid intake was higher than recommended. 
Vitamin intake was higher than the recommended intake for vitamins B1, B2, B6, 
B12, C, and niacin, whilst for folic acid and vitamins D and E it did not reach the 
recommended value [19].  
In a previous study, low vitamin B12 levels (< 200 pmol/l) were found in 
approximately 20% of patients with IDA, including patients with vitamin B12 
deficiency, demonstrated by an increase in homocysteine. Characteristically, the 
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patients included in that group were over 60 years of age. The remaining group of 
patients showed subnormal levels of serum vitamin without metabolic changes of 
vitamin B12 deficiency. This second group included the youngest patients who 
were characterised by IDA with low vitamin B12, low holotranscobalamin, and 
normal homocysteine and methylmalonic acid, excluding vitamin B12 deficiency 
[13]. 
In the present study a group of young adult women with IDA, in whom other 
pathologies were excluded, were investigated before and after oral iron therapy. 
The results demonstrated that serum vitamin B12 increased with iron therapy. 
The increase was significant in patients with the lowest levels of serum vitamin 
(<200 pmol/l). Serum folate also significantly increased, but the baseline levels 
and the values at the end of the study were within the reference range for all 
patients. Other biochemical variables also significantly changed, but most of the 
values were also within the reference range.  These metabolic changes did not 
show a relationship with the Hb increase; however serum vitamin B12 and folate 
were positively correlated. 
Changes in B12 levels upon treatment of IDA have been studied previously with 
mixed conclusions. Whilst Roberts et al. and Akhmeteli et al. [20,21] found B12 
levels to be unchanged in IDA patients during iron therapy, in agreement with our 
results, Harrison [22] found that B12 levels increased with pharmacological iron 
treatment. Several studies, however, concur in finding that B12 levels are reduced 
in IDA patients [7,23,24], with a similar percentage of patients with low B12 levels 
(17.8%) as in our previous studies [7].  
With regards to folic acid, several studies are in agreement with the present study; 
one report [25] indicates that low folate levels related to iron deficiency remitted 
in patients with iron therapy whilst on a low folic acid diet and other observed that 
iron treatment alone corrected abnormalities in the distribution of folate between 
plasma and erythrocytes [26]. Furthermore, a high prevalence of serum folate 
deficiency was reported in a group of 50 IDA patients that improved with iron 
treatment [20]. In animal models contradictory results have been observed. In this 
line, studies in rats found secondary folate deficiency was induced by dietary iron 
deficiency [27–29], however another study did not find such a relationship [30]. 
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Folate and iron are absorbed in the same areas of intestine (upper small intestine). 
Interaction between iron and folate absorption may be provided by the haem 
carrier protein 1, which is both a mammalian haem transporter and a proton-
coupled folate transporter; although its affinity for haem was lower than to folate, 
it has been suggested that its affinity could be increased in IDA [31]. By contrast, 
vitamin B12 absorption is limited to terminal ileum where direct competition with 
iron absorption is minimal.  
In this regard, our study also observed changes in other biochemical variables, 
especially a decrease in lipid variables. As with the present study, other assays 
have found lipid metabolism to be affected by iron deficiency. Choi et al. [32] 
observed, in teenage girls, that serum total cholesterol concentration and serum 
triglycerides were significantly lower in severely anaemic subjects than in controls, 
and that both total cholesterol and triglyceride levels were elevated after iron 
supplementation, whereas in our assay, although cholesterol levels increased after 
treatment, triglycerides did not change. Ozdemir et al. [33] studied premenopausal 
women with IDA, finding that total and LDL cholesterol in the anaemic women 
were lower than in non-anaemic controls, and that levels increased after 
treatment, but remained lower than in control subjects. In contrast, our study 
found HDL levels increased but LDL levels did not change.  These authors also 
hypothesize that low iron status in premenopausal may have a protective effect 
against atherosclerotic heart disease by affecting lipid metabolism. 
Mixed results are seen from studies in experimental models. In rats, Stangl and 
Kirchgessner [34] found that iron depleted rats had lower serum lipoproteins. 
Bristow-Craig et al. [35] found cholesterol and triglycerides to be lower in rats fed 
a low iron diet, and Cunnane and McAdoo [36] found fatty acid metabolism to be 
mildly impaired in moderately iron-deficient rats. However other studies have 
associated iron deficiency with increased levels of serum triglycerides, and studies 
in iron-deficient rats on triglyceride synthesis in the liver do not provide a clear 
picture [37-42].  
Possible interrelationship between vitamin B12, folic acid and iron in 
erythropoiesis has been proposed [24]. Recent discoveries have improved our 
knowledge of iron homeostasis. Hepcidin, a hepatic protein, is the key regulator of 
iron metabolism. In uncomplicated IDA, hepcidin production is decreased. As a 
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consequence, intestinal iron absorption and macrophage and hepatocyte iron 
release are raised. On the contrary, an increase in iron stores stimulates the 
production of hepcidin and, therefore, absorption and release of iron decrease. 
This fine mechanism of iron homeostasis maintains an adequate iron balance.    
Data from our work suggest that iron deficiency could affect many metabolic 
pathways, including vitamin B12, folate, and lipid. These changes normalise after 
iron therapy. In this regard, vitamin B12, folate and lipid metabolisms may have 
been influenced by iron deficiency stimuli, mediated by hepcidin itself or by other 
substances [43-46]. 
In conclusion, serum vitamin B12 and folate levels decreased in iron deficiency and 
increased during treatment with pharmacological iron. The increase in levels of 
vitamin B12 was significant in cases with the lowest levels of serum vitamin B12. 
Other biochemical significant variations were observed, especially in lipid 
metabolism (total cholesterol and HDL cholesterol raised). Healthcare 
practitioners should be aware of these changes in IDA management. The 
mechanisms controlling these changes remain to be explained, but they are 
probably related to the control of iron homeostasis.  
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Table 1. Daily energy and nutrient intake of the study participants at baseline 
 
 Value Recommended  
intake  
Energy (kcal) 2194  415  
Proteins  (% energy) 16.9  2.9  
Carbohydrates (% energy) 38.9  6.4  
Lipids (% energy) 40.7  6.4  
Cholesterol (mg/day) 338 158 <300 
Iron (mg/day) 16.5  5.7 18 
Vitamin B1 (mg/day) 1.7  0.6 0,9 
Vitamin B2 (mg/day) 2.0  0.8 1,4 
Vitamin B6 (mg/day) 2.6  0.9 1,6 
Vitamin B12 (g/day) 10.0  17.1 2,0 
Folic Acid (g/day) 296  118 400 
Vitamin C (mg/day) 144 76 60 
Vitamin D (g/day) 2.8  2.5 5 
Vitamin E (mg/day) 9.0  3.9 12 
Values are presented as means with their standard deviations. Recommended daily 
intake for Spanish women, age 20-39 y [19].
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Table 2. Changes in blood cell counts and iron biomarkers after iron treatment 
 
 Baseline End of treatment Paired t-test, p 
value 
Hemoglobin (g/L) 99.6  9.7 132.3  10.8 <0.001 
MCV (fL) 73.0  6.8 86.6  5.7 <0.001 
MCHC (g/L) 319.9  9.5 337.2  7.2 <0.001 
RDW 17.6  1.8 17.9  4.1 NS 
Serum ferritin (µg/L) 4.25 2.0 23.8  18.6 <0.001 
Serum iron (mcg/dL) 24.7  8.0 70.1  31.0 <0.001 
TIBC (mcg/dL) 479  52 390  55 <0.001 
Transferrin saturation (%) 5.2  1.7 18.2  7.8 <0.001 
sTfR (g/L) 8.62  3.56 3.68  1.39 <0.001 
Platelets (x10^9/L) 297  80 246  54 <0.001 
Values are presented as means with their standard deviations. Comparisons 
between baseline and end of treatment were measured using paired t-test. 
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Table 3. Changes in serum folate and serum vitamin B12 after iron treatment 
 
 N (%) Baseline 
End of 
study 
Increase 
% 
Paired t-test, p 
value 
Serum vitamin B12      
≤200 pmol/l 6 (17.1) 166 ± 24 248 ± 31 49.90 p<0.01 
>200 pmol/l 29 (82.9) 341 ± 96 372 ± 124 9.20 NS 
Total 35 (100) 311 ± 110 351 ± 123 12.90 p<0.05 
Serum folate      
≤13 nmol/l 8 (22.9) 10.6 ± 1.6 16.7 ± 5.6 58.20 p<0.05 
>13 nmol/l 27 (77.1) 19.6 ± 6.3 21.8 ± 7.8 10.90 p<0.05 
Total 35 (100) 17.5 ± 6.8 20.6 ± 7.6 17.50 p<0.01 
Values are presented as means with their standard deviations. Comparisons 
between baseline and end of treatment were measured using paired t-test. 
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Table 4. Changes in biochemical parameters after iron treatment 
 
Biochemical 
parameters 
 
Baseline End of 
treatment 
Paired t-test, p 
value 
Glucose (mg/dL) 83.09  9.34 88.56  9.17 0.012 
Urea (mg/dL) 30.12  6.25 28.09  4.46 0.036 
Creatinine (mg/dL) 0.73  0.09 0.74  0.10 NS 
Uric acid (mg/dL) 3.39  0.66 3.94  0.87 <0.001 
Proteins (g/dL) 7.10  0.45 7.17  0.40 NS 
Albumin (g/dL) 4.50  0.26 4.58  0.27 NS 
Cholesterol (mg/dL) 172.03  28.46 179.65  27.61 0.023 
Triglycerides (mg/dL) 69.21  33.74 64.76  30.74 NS 
HDL-chol (mg/dL) 60.31  12.61 61.03  12.76 0.026 
LDL-chol (mg/dL) 101.95  21.25 106.22  24.82 NS 
Bilirubin (mg/dL) 0.39  0.13 0.56  0.26 <0.001 
Values are presented as means with their standard deviations. Comparisons 
between baseline and end of treatment were measured using paired t-test.  
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Table 5. Hematological parameters according to folate levels at baseline 
 
Values are presented as means with their standard deviations. Comparisons between 
groups by ANOVA.  
 
 
 
 
 
 
 
Folate ≤13 nmol/L Folate >13 nmol/L 
ANOVA, p 
value 
Vitamin B12 pmol/l 206 ± 70 341 ± 103 0.002 
Hb (g/L) 93 ± 14 102 ± 7 0.019 
MCV (fL) 68 ± 5 74 ± 7 0.031 
MCHC (g/L) 314 ± 17 322 ± 7 0.034 
RDW  18 ± 2 17 ± 2 NS 
Serum ferritin (µg/L) 4 ± 1 5 ± 2 NS 
Serum iron (mcg/dl) 19 ± 7 26,75 ± 7,41 0.011 
TIBC (mcg/dl) 469 ± 48 480 ± 54 NS 
Transferrin saturation (%) 4 ± 2 6 ± 2 0.031 
sTfR (g/L) 11 ± 5 8 ± 3 0.024 
Platelets (x109/L) 324 ± 117 285 ± 64 NS 
